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Malaria morbidity and mortality in Ebola-aﬀ ected countries 
caused by decreased health-care capacity, and the potential 
eﬀ ect of mitigation strategies: a modelling analysis
Patrick G T Walker, Michael T White, Jamie T Griﬃ  n, Alison Reynolds, Neil M Ferguson, Azra C Ghani
Summary
Background The ongoing Ebola epidemic in parts of west Africa largely overwhelmed health-care systems in 2014, 
making adequate care for malaria impossible and threatening the gains in malaria control achieved over the past 
decade. We quantiﬁ ed this additional indirect burden of Ebola virus disease.
Methods We estimated the number of cases and deaths from malaria in Guinea, Liberia, and Sierra Leone from 
Demographic and Health Surveys data for malaria prevalence and coverage of malaria interventions before the 
Ebola outbreak. We then removed the eﬀ ect of treatment and hospital care to estimate additional cases and deaths 
from malaria caused by reduced health-care capacity and potential disruption of delivery of insecticide-treated 
bednets. We modelled the potential eﬀ ect of emergency mass drug administration in aﬀ ected areas on malaria 
cases and health-care demand.
Findings If malaria care ceased as a result of the Ebola epidemic, untreated cases of malaria would have increased by 
45% (95% credible interval 43–49) in Guinea, 88% (83–93) in Sierra Leone, and 140% (135–147) in Liberia in 2014. 
This increase is equivalent to 3·5 million (95% credible interval 2·6 million to 4·9 million) additional untreated 
cases, with 10 900 (5700–21 400) additional malaria-attributable deaths. Mass drug administration and distribution of 
insecticide-treated bednets timed to coincide with the 2015 malaria transmission season could largely mitigate the 
eﬀ ect of Ebola virus disease on malaria.
Interpretation These ﬁ ndings suggest that untreated malaria cases as a result of reduced health-care capacity probably 
contributed substantially to the morbidity caused by the Ebola crisis. Mass drug administration can be an eﬀ ective 
means to mitigate this burden and reduce the number of non-Ebola fever cases within health systems.
Funding UK Medical Research Council, UK Department for International Development, Bill & Melinda Gates 
Foundation.
Copyright © Walker et al. Open Access article distributed under the terms of CC BY.
Introduction
Since the Ebola outbreak in Guinea was ﬁ rst reported to 
WHO on March 23, 2014, the virus has spread to nine 
countries, leading to 25 826 cases and 10 704 deaths by 
April 12, 2015.1 Sustained transmission of the virus is 
occurring in three countries in west Africa: Guinea, 
Liberia, and Sierra Leone.2 The high case fatality ratio of 
the disease, coupled with high transmission to health-care 
professionals and low speciﬁ city of early symptoms of 
Ebola virus disease, has placed extraordinary strain on 
health systems in these countries. As a result, few patients 
have access to health-care facilities, with many facilities 
closed. In those still open, fear of the disease has decreased 
outpatient attendance to as low as 10%.3
As a result, the Ebola epidemic in parts of west Africa 
will probably have a much greater eﬀ ect than the direct 
morbidity and mortality eﬀ ects of the disease alone. The 
near cessation of malaria control could lead to a 
resurgence in malaria cases and deaths, reversing 
progress made over the past decade.4 An increase in 
malaria prevalence will also increase the number of 
people who have fever-like symptoms, further com-
plicating the identiﬁ cation and treatment of people with 
Ebola virus disease.
In response to these concerns, the WHO Global 
Malaria Programme has released guidance on temporary 
malaria control measures that should be considered.3 
These measures include strategies to reduce malaria 
morbidity and mortality and to relieve Ebola assessment 
services by reducing the prevalence of non-Ebola-related 
fever in aﬀ ected areas. One recommendation is to deploy 
mass administration of long-lasting artemisinin com-
bination treatment drugs not used as ﬁ rst-line treatment. 
Campaigns would occur for 2–3 months, after which the 
possibility of extending the campaign could be assessed.3 
Such a strategy aims to provide rapid protection from 
malaria in areas where health care is inadequate and to 
avoid the added risk of Ebola virus infection and the 
health-care burden associated with treating malaria in 
clinics. These mass drug administration campaigns are 
being implemented;5 however, the probable eﬀ ect of such 
strategies has not been properly assessed.
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We estimated the eﬀ ect that cessation of usual health-
care provision for malaria as a result of the Ebola 
epidemic has had on malaria transmission, case 
numbers, and deaths. We then assessed the beneﬁ t of a 
mass drug administration campaign initiated in 2015 to 
reduce malaria-attributable deaths and the burden of 
malaria-attributable fever on the health systems in the 
three aﬀ ected countries.
Methods
Estimation of the eﬀ ect of health-system failure on 
malaria transmission and prevalence
We used a previously reported model6 to model malaria 
transmission in Guinea, Liberia, and Sierra Leone from 
2000, to the start of the Ebola outbreak in March, 2014 
(appendix). All model runs were done at the level of the 
second administrative unit in Sierra Leone (districts) and 
Liberia (counties) and the ﬁ rst administrative unit in 
Guinea (regions). The model was ﬁ tted to match 
estimates of parasite prevalence by microscopy in 
children younger than 5 years, using the proportion of 
fevers in these children treated with antimalarial drugs 
and use of insecticide-treated bednets in each of the three 
countries as input parameters. These data were obtained 
from the most recent ﬁ nal report of a Demographic 
Health Survey (DHS) or Malaria Indicator Survey (MIS; 
appendix). To capture the decrease in malaria trans-
mission that has occurred since 2005, we also in-
corporated data about use of insecticide-treated bednets 
from older DHS and MIS surveys, linearly interpolating 
between these estimates for years in which surveys were 
not available.
We used the model to estimate the number of clinical 
malaria cases that would have occurred up to the end of 
November, 2014, in the absence of the Ebola epidemic, 
using a previously ﬁ tted relation between parasite 
prevalence and clinical incidence.6 We then compared 
this estimate with a scenario in which health systems no 
longer provide malaria treatment after 2 months of 
sustained transmission of Ebola virus based on patient 
database records published by WHO1 (from May, 2014, 
onwards in Guinea, and July, 2014, onwards in Sierra 
Leone and Liberia) to estimate the increase in malaria 
incidence attributable to the ongoing Ebola epidemic in 
2014. We estimated the additional number of malaria 
cases caused by the Ebola epidemic by multiplying the 
age-stratiﬁ ed case incidence and age-stratiﬁ ed population 
estimates for each administrative unit. We assessed 
uncertainty in the estimates by use of Bayesian methods, 
presented as 95% credible intervals (CrI).
The epidemic probably disrupted the distribution of 
bednets in aﬀ ected areas, thereby reducing their 
eﬀ ectiveness because nets degrade over time as a result 
of wear and tear and waning insecticide concentration.
We therefore used an existing model of the eﬀ ect of 
insecticide-treated bednets7 to explore the potential eﬀ ect 
of cessation of bednet distribution, comparing a situation 
in which bednets are replenished every 3 years, with a 
third of the covered population receiving a net each year 
and at 20% attrition of net use per year between rounds, 
with a situation in which bednet distribution ceases as a 
result of the Ebola epidemic.
Estimation of the eﬀ ect of health-systems failure on the 
likelihood of death after clinical disease
We used a decision tree model to estimate the risk of 
death from a clinical case of malaria under health 
systems of diﬀ ering levels of functioning (appendix). We 
drew parameters for the decision tree from the country-
speciﬁ c DHS and MIS population surveys, Delphi 
surveys,8 and the World Malaria Report.9 We used the 
model to estimate malaria-attributable mortality in each 
administrative unit in the presence of a health system 
with pre-Ebola capacity (using country-speciﬁ c treatment 
rates) and in the absence of both clinic or hospital 
capacity for malaria treatment. We then obtained the 
additional numbers of malaria-attributable deaths 
caused by the Ebola epidemic by multiplying mortality 
by population size, taking into account the age-
distribution of the population and of malaria cases in 
each administrative unit. We calculated uncertainty in 
the estimates by combining uncertainty in case numbers 
and uncertainty in parameters in the decision tree model 
to give approximate 95% CrI.
Modelling the effect of emergency mass drug 
administration
We simulated mass drug administration campaigns in 
2015 involving either three or six rounds of complete 
doses of either artesunate–amodiaquine (the recom-
mended ﬁ rst-line treatment in Guinea, Sierra Leone, 
and Liberia) or the long-acting antimalarial drug 
dihydroartemisinin–piperaquine, both given at 
monthly intervals.10 We considered three levels of 
coverage of mass drug administration (30%, 50%, and 
70%) of the at-risk population within each administrative 
unit in each round and we assumed that the coverage 
between rounds was correlated (eg, the same 30% of 
individuals received the drug each round while the 
same 70% received no treatment). We varied the 
beginning of this campaign between January and 
September for each country and compared the eﬀ ect on 
malaria cases and deaths of an immediate campaign 
(beginning in January, 2015) with one for which the 
timing of the campaign was chosen to minimise 
malaria burden and health-system demand over the 
whole year (beginning in June, 2015).
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
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Results
With the exception of some urban centres such as 
Conakry in Guinea, malaria is hyperendemic in almost 
all areas where Ebola virus transmission is sustained 
(ﬁ gure 1A), with population-based estimates of 
parasite prevalence in children younger than 5 years of 
43·9% in Guinea, 27·8% in Liberia, and 42·9% in 
Sierra Leone.11–13
In Guinea and Sierra Leone, where malaria trans-
mission is highly seasonal, the sharp rise in cases of 
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Figure 1: Distribution of Ebola virus disease, malaria prevalence, malaria treatment coverage, and estimated eﬀ ect of Ebola virus disease on malaria mortality 
in Guinea, Liberia, and Sierra Leone
(A) Cases of Ebola virus disease up to Feb 1, 2015, with data from patient databases except for Liberia from Nov 17, 2014, for which data are from situation reports 
only.1 (B) Prevalence of malaria in children younger than 5 years according to slide microscopy. (C) Proportion of fevers treated with malaria in children younger than 
5 years, from both population-based surveys, and our estimates of the additional malaria mortality caused by Ebola virus disease (D). 
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Figure 2: Eﬀ ect of health-systems failure on incidence of untreated malaria
For Guinea (A), Liberia (B), Sierra Leone (C), and the combined total (D). Pink bars show the number of cases untreated and red bars show the number of cases treated 
when the system is functioning normally, blue bars show additional cases caused by increases in transmission from the additional untreated cases. The green lines 
show the present status of the Ebola epidemic (probable and conﬁ rmed cases from patient databases), the blue lines show Ebola cases from WHO situation reports.
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Figure 3: Eﬀ ect of health-systems failure on malaria deaths
For Guinea (A), Liberia (B), Sierra Leone (C), and the combined total (D). Red bars show additional deaths in individuals who would otherwise have been treated with an 
artemisinin-based combination therapy (ACT) and recovered, pink bars show additional deaths in individuals who would not have received ACT or failed to respond to 
ACT but would have otherwise recovered after hospital care, and blue bars show additional deaths caused by the additional malaria cases attributable to increased 
malaria transmission. Green lines show probable and conﬁ rmed Ebola cases from patient databases, blue lines show Ebola cases from WHO situation reports.
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Ebola virus disease in the middle of 2014 was estimated 
to have coincided with the peak months of malaria 
transmission. In Liberia, malaria is endemic for most of 
the year, albeit at lower overall levels than in the Guinea 
and Sierra Leone (ﬁ gure 2). Thus, the timing of the Ebola 
epidemic has probably exacerbated the burden on health 
systems in these countries and hence had a substantial 
eﬀ ect on the number of malaria patients who received 
treatment. If the Ebola epidemic led to a complete 
cessation of malaria treatment, we estimated that the 
number of untreated malaria cases will have increased by 
45% (95% CrI 43–49) in Guinea, 88% (83–93) in Sierra 
Leone, and 140% (135–147) in Liberia in 2014, representing 
a total of 3·5 million (2·6 million to 4·9 million) 
additional untreated cases: 1·6 million (1·1 million to 
2·4 million) in Guinea, 1·3 million (0·9 million to 
1·9 million) in Sierra Leone, and 0·52 million 
(0·36 million to 0·76 million) in Liberia. This increase 
translates to an increase in the incidence of untreated 
clinical malaria of 160 (103–221) cases per 1000 people in 
Guinea Liberia Sierra Leone Total
Cases, 
millions
Deaths Cases, 
millions
Deaths Cases, 
millions
Deaths Cases, 
millions
Deaths
Baseline 5·3
(3·8–7·2)
17 200
(10 300–28 400)
1·6
(1·1–2·2)
4300
(2700–6900)
3·4
(2·3–4·6)
9900
(5900–16 400)
10·3
(8·1–12·7)
31 800
(20 500–47 800)
Additional 0·3
(0·2–0·6)
6200
(3100–11 700)
0·2
(0·1–0·4)
3000
(1600–6000)
0·3
(0·1–0·6)
5300
(2600–9900)
0·9
(0·5–1·3)
14 800
(8300–24 800)
Total 5·6
(3·9–7·8)
23 600
(13 700–39 800)
1·8
(1·2–2·5)
7300
(4400–12 700)
3·7
(2·5–5·1)
15 200
(8700–26 100)
11·5
(8·7–14·0)
46 400
(28 900–73 000)
3-month MDA from January
Dihydroartemisinin–
piperaquine, 30% 
coverage
5·3
(3·7–6·8)
22 800
(13 400–34 100)
1·7
(1·0–2·2)
7000
(3800–10 800)
3·5
(2·3–4·5)
14 400
(9100–22 100)
10·5
(7·4–13·1)
44 100
(26 400–67 000)
Dihydroartemisinin–
piperaquine, 50% 
coverage
5·0
(3·3–6·2)
21 200
(12 400–30 700)
1·5
(1·0–2·0)
6600
(3800–10 700)
3·3
(2·1–4·3)
13 500
(7400–20 200)
9·9
(6·5–12·2)
41 200
(23 700–61 500)
Dihydroartemisinin–
piperaquine, 70% 
coverage
4·4
(2·9–5·8)
19 200
(11 600–28 100)
1·3
(0·9–1·8)
5500
(3200–8200)
3·0
(1·9–4·0)
12 800
(7000–19 500)
8·7
(5·7–11·4)
37 400
(22 000–55 600)
Artesunate–amodiaquine, 
70% coverage
4·5
(3·2–6·3)
20 000
(12 100–28 400)
1·4
(0·9–1·8)
6000
(3300–8800)
3·1
(2·0–4·1)
13 300
(7200–19 700)
8·9
(6·2–12·1)
39 400
(22 700–56 500)
3-month MDA from July
Dihydroartemisinin–
piperaquine, 30% 
coverage
4·4
(3·1–5·5)
18 600
(10 800–28 800)
1·6
(1·0–2·1)
6500
(3500–9500)
3·1
(2·0–4·0)
12 700
(6900–21 100)
9·2
(6·1–11·7)
37 800
(21 300–58 500)
Dihydroartemisinin–
piperaquine, 50% 
coverage
3·5
(2·3–4·4)
15 000
(9200–21 600)
1·4
(0·9–1·8)
5900
(3200–8600)
2·7
(1·7–3·5)
11 600
(6700–16 400)
7·7
(5·0–9·6)
32 400
(19 200–46 000)
Dihydroartemisinin–
piperaquine, 70% 
coverage
2·7
(1·9–3·4)
11 400
(6700–17 900)
1·2
(0·8–1·5)
4900
(2700–7700)
2·2
(1·5–2·9)
9700
(5800–13 800)
6·0
(4·2–7·9)
26 100
(15 500–38 300)
Artesunate–amodiaquine, 
70% coverage
3·7
(2·5–5·2)
16 400
(10 300–24 500)
1·4
(0·9–1·8)
6100
(3600–9300)
2·9
(1·8–3·8)
12 100
(6500–17 900)
7·9
(5·2–10·6)
34 500
(20 600–50 200)
6-month MDA from April
Dihydroartemisinin–
piperaquine, 30% 
coverage
3·9
(2·7–5·0)
16 400
(10 100–23 600)
1·2
(0·8–1·6)
5200
(3200–7400)
2·5
(1·7–3·5)
7300
(4400–10 400)
7·6
(5·3–10·8)
28 800
(17 900–40 700)
Dihydroartemisinin–
piperaquine, 50% 
coverage
2·8
(1·9–3·7)
12 300
(7500–17 400)
0·9
(0·6–1·2)
3700
(2000–5800)
1·8
(1·3–2·4)
5300
(2800–8300)
5·5
(3·8–7·1)
21 300
(12 700–30 200)
Dihydroartemisinin–
piperaquine, 70% 
coverage
1·8
(1·3–2·4)
7900
(4900–10 900)
0·6
(0·4–0·8)
2500
(1400–4000)
1·3
(0·8–1·6)
3600
(2100–5900)
3·8
(2·8–4·9)
14 000
(8700–20 200)
Artesunate–amodiaquine, 
70% coverage
3·0
(1·9–3·9)
12 300
(7800–18 500)
0·9
(0·5–1·2)
3700
(2000–6000)
1·9
(1·3–2·5)
5400
(2900–8800)
5·7
(3·7–7·4)
21 200
(13 000–33 000)
Data are n (95% credible interval). Baseline shows the estimates if health systems return to the level of functioning from before the Ebola epidemic. The additional cases are 
those that are predicted to occur if the health systems continue not to function throughout 2015 and no other remedial action is taken. The mass drug administration (MDA) 
scenarios show the total cases that are predicted without a return to a functioning health system.   
Table: Predicted malaria cases and deaths in 2015, by country
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Guinea, 207 (139–296) cases per 1000 people in Sierra 
Leone, and 119 (81–172) cases per 1000 people in Liberia. 
Although Liberia has lower and less seasonal 
transmission (ﬁ gure 1B), it had the highest treatment 
coverage before the present Ebola outbreak (55·7% 
receiving antimalarial treatment for fever compared with 
28·1% in Guinea and 44·1% in Sierra Leone; 
ﬁ gure 1C)11,12,14 and hence we estimated it to have had the 
highest proportional increase in untreated cases of the 
three countries. In all three countries, most untreated 
cases were in young children (48% [44–51] in children 
younger than 5 years, 38% [36–40] in children aged 
5–15 years, and 14% (13–16) in people older than 15 years), 
resulting in little overlap with cases of Ebola virus disease 
(13·8% of which occur in children younger than 
15 years).2
Most additional untreated cases caused by the Ebola 
epidemic would have occurred in the absence of Ebola 
virus disease but would have been treated because the 
high prevalence of malaria means that most transmission 
occurs among individuals who are suﬃ  ciently immune 
to be asymptomatic.15,16 However, a small proportion of 
the additional untreated cases are new cases (18% [13–24] 
in Guinea, 11% [7–15] in Liberia, and 14% [10–18] in 
Sierra Leone; ﬁ gure 2), which are predicted to occur 
because of the eﬀ ect of reduced malaria treatment on 
malaria transmission (ﬁ gure 2).
We estimated that cessation of distribution of insec-
ticide-treated bednets because of the Ebola epidemic 
would lead to a further 0·84 million (0·80 million to 
1·01 million) cases of malaria in 2014, representing a 
9·5% (8·7–12·8) increase. Moreover, this additional 
burden could accelerate sharply in 2015 if bednet use 
does not recover, with an estimated 2·7 million 
(1·9 million to 3·8 million) additional cases if coverage 
does not return to previous levels before the rainy 
season (appendix).
In the absence of clinic and hospital care, we estimated 
an increase in malaria-attributable mortality of 35% 
(25–49) in Guinea, 50% (34–71) in Sierra Leone, and 62% 
(40–94) in Liberia. This increase represents 10 900 
additional malaria deaths (5700–21 400) over this period: 
5600 (3000–11 100) in Guinea, 3900 (2000–7600) in Sierra 
Leone, and 1500 (700–2900) in Liberia (ﬁ gure 1D). Most of 
Figure 4: Estimated eﬀ ect of mass drug administration on malaria deaths during 2015
For Guinea (A), Liberia (B), Sierra Leone (C), and the combined total (D). Red bars show predicted monthly malaria deaths in the absence of mass drug administration or 
any malaria treatment, blue bars show predicted monthly malaria deaths with mass drug administration with dihydroartemisinin–piperaquine for 3 months beginning 
in January 2015, the green bars show mass drug administration for 3 months beginning in June 2015, and the purple bars show mass drug administration for 6 months 
beginning in January 2015. All scenarios assume 70% coverage of the population and that the health system does not continue to function throughout the year.
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these deaths are estimated to occur in people who would 
otherwise have recovered because of prompt access to 
ﬁ rst-line treatment with an eﬀ ective antimalarial drug 
(ﬁ gure 3). The small eﬀ ect that disruption of ﬁ rst-line 
treatment has on transmission also means these numbers 
can be scaled to approximate any intermediate scenario 
where health-care provision has not been entirely 
disrupted (eg, a 75% reduction in health-care provision 
would result in 8000 [4200–15 700] additional malaria 
deaths, representing 73·4% [72·5–74·3] of the total in the 
absence of any provision; appendix). By contrast, 
disruption of delivery of insec ticide-treated bednets 
predominantly aﬀ ects malaria transmission and hence 
additional disruption increases the number of cases 
overall. As a result, additional mortality caused by 
disruption of bednet delivery is less sensitive to how well 
the health system functions compared with before the 
Ebola epidemic, with the additional cases in our 
simulation leading to an additional 3900 deaths 
(2700–5500) in the absence of any health system or 3700 
(2500–5100) additional deaths when the number of cases 
of uncomplicated malaria treated and hospital admissions 
for severe malaria has fallen by only 50%. 
If usual health-care provision remains disrupted 
throughout 2015, we predict 46 400 (28 900–73 000) 
further deaths from malaria across the three countries 
compared with an estimated 31 800 deaths (20 500–47 800) 
if health systems return to function at the level before the 
Ebola epidemic (table).
Assuming that Ebola transmission will continue to 
decrease and health systems will begin to recover, our 
simulations suggest that a campaign of mass drug 
administration (assuming 70% coverage with arte-
mether–piperaquine) in three rounds in consecutive 
months beginning in January, 2015, would reduce the 
burden of febrile malaria cases in the short term, 
leading to a 40% reduction in malaria cases and deaths 
in the ﬁ rst 6 months of 2015. However, because malaria 
transmission peaks at around July in these countries, 
our simulations support WHO’s guidance that, after 
two to three rounds, the need for continuing mass drug 
administration should be assessed (ﬁ gure 4). If the 
health system remains compromised throughout 2015, 
we estimate that six rounds of mass drug administration 
would reduce the number of malaria attributable deaths 
to 21 200 (13 000–33 000) with artesunate–amodiaquine 
or to 14 000 (8700–20 200) with artemether–piperaquine 
at 70% coverage (table).
Disruption to delivery of insecticide-treated bednets in 
2014 will probably have a large eﬀ ect on both malaria 
cases and deaths in 2015, and hence providing bednets as 
early as possible in the year, either alongside mass drug 
administration or in a separate top-up campaign will 
probably greatly mitigate the eﬀ ect of Ebola virus disease 
on malaria (appendix). In our simulation, a campaign to 
replace all insecticide-treated bednets and return 
coverage to pre-Ebola levels in February, 2015, reduced 
the number of additional deaths attributable to disruption 
of bednet distribution by 65% (64–66).
Discussion
In a scenario in which no patients with malaria receive 
ﬁ rst-line treatment or hospital care, we estimate that the 
Ebola epidemic could have resulted in many additional 
deaths in 2014 in Guinea, Liberia, and Sierra Leone. 
Because of the low proportion of deaths attributable to 
new cases of infection, this worst-case scenario provides 
a readily adjustable benchmark with which to assess the 
probable eﬀ ect of health-system disruption if the real-life 
eﬀ ect on treatment and hospital admission can be 
assessed more accurately in the aftermath of the crisis.
Our estimate does not incorporate the additional eﬀ ect 
of disruption to delivery of bednets, which we showed 
could result in an increase in malaria incidence, 
emphasising the importance of ensuring the bednets are 
in place for the forthcoming transmission season. It also 
excludes the eﬀ ect of Ebola virus disease on maternal 
malaria morbidity. Malaria has been estimated to cause 
430 000 infections during pregnancy and 31 100 low 
birthweight deliveries if adequate health care is not 
available in these three countries based on 2010 levels of 
transmission.17 Provision of intermittent preventive 
treatment for pregnant women is high in Sierra Leone 
(61·7% of pregnant women) and Liberia (47·6%),12,14 
although lower in Guinea (17·8%);11 therefore, Ebola 
virus disease preventing access to health care will 
probably have a substantial eﬀ ect on malaria morbidity 
in pregnant women and babies. As a result, the overall 
indirect eﬀ ect of Ebola virus disease on malaria will 
probably be equal or greater than the direct eﬀ ect of the 
virus itself.
By including the additional eﬀ ect of Ebola virus disease 
on health care for other common diseases in the aﬀ ected 
areas, as well as the eﬀ ect that a non-functioning health 
system has on broader maternal and infant health, these 
Panel: Research in context
Systematic review
We searched PubMed with the terms “malaria” and “Ebola”, 
to identify estimates of the eﬀ ect of the ongoing Ebola 
epidemic on malaria burden, published up to Feb 1, 2015. 
We found no relevant studies and one news report,4 which 
did not attempt to estimate the eﬀ ect of the Ebola epidemic 
on malaria.
Interpretation
We estimate that the indirect eﬀ ect of the Ebola epidemic on 
malaria morbidity and mortality is probably of similar size as 
the public health burden directly caused by Ebola virus 
disease. This ﬁ nding suggests that measures to prevent 
malaria infection, such as the emergency mass drug 
administration suggested by WHO, are urgently needed while 
health systems recover.
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estimates provide an indication of the true size of the 
humanitarian crisis caused by the outbreak of Ebola 
virus disease (panel). They also suggest that these eﬀ ects 
will probably continue well after the epidemic has been 
contained while both the health system itself, and trust 
in it, recover.
Our results also show the potential eﬀ ect of mass drug 
administration, as recently recommended in WHO 
guidance for malaria control in aﬀ ected areas. Such 
strategies are logistically challenging and, particularly 
in an Ebola epidemic, need careful and thorough social 
mobilisation and community engagement. However, we 
estimate that mass drug administration could sub-
stantially reduce additional malaria burden. An 
additional beneﬁ t of preventive interventions is the 
corresponding reduction in the need for treatment and 
hence a reduction in the burden imposed on already 
strained health systems. One of the key factors 
determining the success of such a campaign will be the 
level of coverage achieved. We assumed 70% coverage, 
but our results show that lower coverage could still have 
a substantial eﬀ ect. Our results also provide some 
guidance for the timing of the campaigns. Immediate 
implementation of these strategies, as is occurring in 
aﬀ ected areas in Sierra Leone,5 is likely to help with the 
pressing short-term task of rapidly identifying Ebola 
cases by alleviating the burden of malaria on the health 
system.
However, in Sierra Leone and Guinea, malaria 
transmission is highly seasonal, with cases expected to 
have fallen around November and December, 2014. 
Malaria cases will begin to rise again at the start of the 
next rainy season (May and June, 2015) and hence could 
provide an additional challenge to ending the Ebola 
epidemic. Thus, the feasibility of extending mass drug 
administration campaigns beyond three rounds should 
be carefully considered.
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